News
August 2011: ReveraGen BioPharma Selected as Awardee for Inaugural National Institutes of Health’s Therapeutics for Rare and Neglected Diseases Program for its Novel Dissociative Glucocorticoid Analogue
Rockville, MD – ReveraGen BioPharma, Inc., a biopharmaceutical company developing alternatives to traditional steroid compounds, including dissociative glucocorticoid analogues for use in muscular dystrophy, has been selected by the National Institutes of Health’s (NIH) Therapeutics for Rare and Neglected Diseases
More >August 2011: Former MedImmune exec becomes CEO of startup
Under-the-radar ReveraGen BioPharma Inc., a Rockville-based biotech, has recruited former MedImmune executive Edward Connor to helm the small operation, which hopes to bring a better treatment for Duchenne muscular dystrophy to market.
More >
